Current guidelines for selecting case subjects for molecular testing include age of diabetes diagnosis before 25 years, parental history of diabetes, and noninsulin dependence (8).
The molecular testing included here is part of the ELN standardized reporting system previously shown to improve prognostic stratification following treatment with chemotherapy alone.
Indications for clinical molecular testing include establishment of the correct diagnosis if there is no family history and if there are atypical features on imaging; exclusion testing for potential living-related donors and prenatal/pre-implantation genetic diagnosis [ 28].
The limitations of molecular testing include the possibility of false-positive results caused by specimen contamination during processing and false-negative results from primer mismatch or inhibitors in the specimen.
Previous molecular testing included aCGH, which revealed a paternally inherited 125-kb copy number gain within chromosome 12q24.12; she had a normal chromosome analysis, an unrevealing targeted microcephaly gene panel, and normal thyroid function studies, plasma amino acids, urine organic acids, and urine mucopolysaccharides.
Molecular tests including TB-PCR, HSV-PCR, and enterovirus RT-PCR were negative.
Dengue positive samples were determined based on physician diagnosis as well as molecular tests including RT-PCR viral RNA.
Testing for the presence of oncogenic HPV DNA offers improved sensitivity, though lower specificity, than cytology alone [ 4] while the next generation of molecular tests, including those with limited genotyping capability, may improve upon this [ 5].
Molecular tests included nested PCR (nPCR) for HHV-6 HHV-7, picornavirus and adenovirus, multiplex real-time PCR for varicella zoster [VZV] and herpes simplex viruses-1 [HSV-1] and −2, tandem multiplex real-time PCR for influenza A and B virus, and for flaviviruses.
As a pilot study we performed comprehensive molecular diagnostic testing, including the study of the FMR1 and FMR2 repeat regions, copy number variant analysis in a collection of 50 Spanish ASD cases and mutation screening using targeted next generation sequencing-based techniques in 44 out of the total cohort.
